Exxua, a Novel Treatment for Major Depressive Disorder, Gets FDA Approval
The FDA has approved Exxua (gepirone HCl extended-release tablets) for the treatment of major depressive disorder in adults.
Source: clinicaladvisor.com
Kramer Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kramer Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kramer Pharmaceuticals Today - Breaking & Trending Today
Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults
/PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in...
Source: prnewswire.com
Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUAtm, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults
Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA)...
Source: lelezard.com
Global CNS Therapeutics Strategic Business Report 2023: Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
/PRNewswire/ -- The "CNS Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CNS...
Source: prnewswire.com
Global CNS Therapeutics Strategic Business Report 2023: Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
DUBLIN, June 30, 2023 /PRNewswire/ -- The "CNS Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for CNS Therapeutics estimated
Source: benzinga.com